Triple negative breast cancer: The kiss of death

Oncotarget

Volumn 8, Issue 28, 2017, Pages 46652-46662

  Jitariu, Adriana Andreea ^a   Cîmpean, Anca Maria ^a   Ribatti, Domenico ^b,c   Raica, Marius ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Metastases; Progression; Therapeutic targets; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AURORA A KINASE; CAVEOLIN 1; CAVEOLIN 2; CD133 ANTIGEN; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; DUAL SPECIFICITY PHOSPHATASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MICRORNA 221; MICRORNA 222; P CADHERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TAXANE DERIVATIVE; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR GATA 3; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VIMENTIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CELL HETEROGENEITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; NONHUMAN; ONCOGENE; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; ANIMAL; CANCER GRADING; FEMALE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85022182908     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16938     Document Type: Review

References (90)

1. Margan MM, Jitariu AA, Cimpean AM, Nica C, Raica M. Molecular Portrait of the Normal Human Breast Tissue and Its Influence on Breast Carcinogenesis. J Breast Cancer. 2016; 19: 99-111
2. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 6: vi7-12
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, et al. Molecular portraits of human breast tumors. Nature. 2000; 406: 747-752
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 10869-10874
5. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100: 8418-8423
6. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006; 7: 127
7. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-1948
8. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, et al. Basallike and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology. 2010; 24: 157-167
9. Elsawaf Z, Sinn HP. Triple-Negative Breast Cancer: Clinical and Histological Correlations. Breast Care (Basel). 2011; 6: 273-278
10. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009; S 2: S73-81
11. Tariq K, Farhangi A, Rana F. TNBC vs Non-TNBC: A Retrospective Review of Differences in Mean Age, Family History, Smoking History, and Stage at Diagnosis. Clinical Advances in Hematology and Oncology. 2014; 12: 377-381
12. Ishikawa Y, Horiguchi J, Toya H, Nakajima H, Hayashi M, Tagaya N, Takeyoshi I, Oyama T. Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features. Cancer Sci. 2011; 102: 656-662
13. Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health. 2012; 4: 511-520
14. Langlands F, Cornford E, Rakha E, Dall B, Gutteridge E, Dodwell D, Shaaban AM, Sharma N. Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. Br J Radiol. 2016; 20140644
15. Benson R, Madan R, Julka PK, Rath GK. Metaplastic carcinoma of breast: A series of seven patients from a tertiary care center and review of literature. Gulf J Oncolog. 2016; 1: 74-76
16. Xu H, Eirew P, Mullaly SC, Aparicio S. The Omics of Triple-Negative Breast Cancers. Clinical Chemistry. 2014; 60: 122-133
17. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008; 14: 8010-8018
18. Lee E, McKnean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G. Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young Women. American Society of Clinical Oncology. 2011; 29: 4373-4380
19. Lips EH, Mulder L, Oonk A, van der Kolk LE, Horgervorst FBL, Imholz ALT, Wesseling J, Rodenhuis S, Nederlof PM. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutations carriers. BJC. 2013; 108: 2172-2177
20. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol. 2007; 14: 419-430
21. O'Reilly EA, Gubbins L, Sharma S, Tully R, Zhing Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA, Clinical. 2015; 3: 257-275
22. Dillon JL, Mockus SM, Ananda G, Spotlow V, Wells WA, Tsongalis GJ, Marotti JD. Somatic gene mutation analysis in triple negative breast cancers. Breast. 2016; 29: 202-207
23. Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fugua S, Kent Osborne C, Mills GB et al. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016; 158: 441-454
24. Meseure D, Vacher S, Drak Alsibai K, Trassard M, Nicolas A, Leclere R, Lerebours F, Guinebretiere JM, Marangoni E, Lidereau R, Bieche I. Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinoma Subtypes. Cancer Microenviron. 2016; 9: 107-118
25. Davion SM, Siziopikou KP, Sullivan ME. Cytokeratin 7: a re-evaluation of the 'tried and true' in triple-negative breast cancers. Histopathology. 2012; 61: 660-666
26. Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT. GATAbinding protein enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology. 2015; 67: 245-254
27. Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, Resetkova E, Hunt KK, Deavers MT. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology. 2013; 62: 267-274
28. Karihtala P, Kaupilla S, Soini Y, Arja-Jukkola-Vuorinen. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer. 2011; 11: 262
29. Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, Potapova O, Vansant G, Monforte J, Daraselia N. Exploring molecular pathways of triple-negative breast cancer. Genes Cancer. 2011; 2: 870-879. doi: 10.1177/1947601911432496
30. Bonzanini M, Moreli L, Bonandini EM, Leonardi E, Pertile R, Dalla Palma P. Cytologic features of triple-negative breast carcinoma. Cancer Cytopathol. 2012; 120: 401-409
31. Maeda T, Nakanishi Y, Hirotani Y, Fuchinoue F, Enomoto K, Sakurai K, Amano S, Nemoto N. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med Mol Morphol. 2016; 49: 11-21
32. Li Z, Ren M, Tian J, Jiang S, Liu Y, Zhang L, Wang Z, Song Q, Liu C, Wu T. The differences in ultrasound and clinicopathological features between basal-like and normallike subtypes of triple negative breast cancer. PLoS One. 2015; 10: e0114820
33. Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer. 2013; 13: 403
34. Kim S, Jung WH, Koo JS. Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer. Tumor Biol. 2012; 33: 1681-1694
35. Ryu DW, Lee CH. Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death. J Korean Surg Soc. 2012; 83: 187-195
36. Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X. CK 5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol. 2011; 1: S129-134
37. Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am. 2014; 23: 567-577
38. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013; 18: 123-133
39. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009; 15: 2302-2310
40. De Summa S, Pinto R, Sambiasi D, Petriella D, Paradiso V, Paradiso A, Tommasi S. BRCAness: a deeper insight into basal-like breast tumors. Ann Oncol. 2013; S8: viii13-viii21
41. Pogoda K, Niwinska A, Murawska M, Pienkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013; 30: 388
42. Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triplenegative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press). 2016; 8: 93-107
43. Mirzania M. Approach to the Triple Negative Breast Cancer in New Drugs Area. Int J Hematol Oncol Stem Cell Res. 2016; 10: 115-119
44. Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F. Do platinum salts fit all triple negative breast cancers? Cancer Treat Rev. 2016; 48: 34-41
45. Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cencer Subtypes: A Systematic Review. JAMA Oncol. 2016; 2: 1354-1360
46. Mouh FZ, Mzibri ME, Slaoui M, Amrani M. Recent Progress in Triple Negative Breast Cancer Research. Asian Pac J Cancer Prev. 2016; 17: 1595-1608
47. Kwast AB, Liu L, Roukema JA, Voogd AC, Jobsen JJ, Coebergh JW, Soerjomataram I, Siesling S. Increased risks of third primary cancers of non-breast origin among women with bilateral breast cancer. Br J Cancer. 2012; 107: 549-555
48. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429-4434
49. Choi YJ, Seong MH, Choi SH, Kook SH, Kwag HJ, Park YL, Park CH. Ultrsound and clinicopathological characteristics of triple-negative breast cencers. J Breast Cancer. 2011; 14: 119-123
50. Li CY, Wang P, Zhang S, Liu Y, Zhang J. Clinicopathological features and prognosis of triplenegative breast cancer. [Article in Chinese]. Zhonghua Zhong Liu Za Zhi. 2013; 35: 463-467
51. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW. Characteristics and outcomes according to the molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012; 21: 50-57
52. Matro JM, Li T, Cristofanilli M, Hughes ME, Ottesen RA, Weeks JC, Wong YN. Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. Clin Breast Cancer. 2015; 15: 1-7
53. Laimito KR, Gamez-Pozo A, Sepulveda J, Manso L, Lopez-Vacas R, Pascual T, Fresno Vara JA, Ciruelos E. Characterization of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. Ecancermedicalscience. 2016; 10: 632
54. Caliari D, Zappulli V, Rasotto R, Cardazzo B, Frassineti F, Goldschmidt MH, Castagnaro M. Triple-negative vimentinpositive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer. BMC Vet Res. 2014; 10: 185
55. Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia. 2012; 17: 65-77
56. Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L, Cyrta J, Piscuoglio S, Wen HC, Lim RS, Shen R, Schultheis AM, Wen YH, Edelweiss M, et al. Genomic landscape of adenoid cystic carcinoma of the breast. J Pathol. 2015; 237: 179-189
57. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocana A, Pandiella A. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene. 2014; 33: 148-156
58. Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, Herndon J, Cohoon TJ, Fleming T, et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 2014; 124: 5411-5423
59. Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, Leng X, Zhang C, Sun R et al. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer. 2014; 13: 207
60. Chinchar E, Makey KL, Gibson J, Chen F, Cole SA, Megason GC, Vijayakumar S, Miele L, Gu JW. Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc Cell. 2014; 6: 12
61. Luan YY, Liu ZM, Zhong JY, Yao RY, Yu HS. Effect of grape seed proanthocyanidins on tumor vasculogenic mimicry in human triple-negative breast cancer cells. Asian Pac J Cancer Prev. 2015; 16: 531-535
62. Plantamura I, Casalini P, Dugnani E, Sasso M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli C, Barajon I, Bianchi F, Triulzi T, Agresti R, et al. PDGFRbeta and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. Mol Oncol. 2014; 8: 968-981
63. Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barille-Nion S, Georgakoudi I, Dagg A, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, et al. ADAM8, expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med. 2014; 6: 278-294
64. Davuluri G, Schiemann WP, Plow EF, Sossey-Alaoui K. Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1alphamediated angiogenesis. JAKSTAT. 2015; 3: e1009276
65. Xiang L, Gilkes DM, Chaturvedi P, Luo W, Hu H, Takano N, Liang H, Semenza GL. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J Mol Med (Berl). 2014; 92: 151-164
66. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, et al. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013; 19: 1281-1289
67. Danza K, Pilato B, Lacalamita R, Addati T, Giotta F, Bruno A, Paradiso A, Tommasi S. Angiogenic axis angiopoetins/Tie2 and VEGF in familial breast cancer. Eur J Hum Genet. 2013; 21: 824-830
68. Davis AA, Kaklamani VG. Metabolic syndrome and triplenegative breast cancer: a new paradigm. Int J Breast Cancer. 2012; 2012: 809291
69. Liu HT, Ma R, Yang QF, Du G, Zhang CJ. Lymphangiogenic characteristics of triple negativity in node-negative breast cancer. Int J Surg Pathol. 2009; 17: 426-431
70. Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, et al. Phase II Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist. 2016; 22: 25-32
71. Livasy CA. Triple-Negative Breast Carcinoma. Surg Pathol Clin. 2009; 2: 247-261
72. Cerqueira OL, Truesdell P, Baldassare T, Vilella-Arias SA, Watt K, Meens J, Chander H, Osorio CA, Soares FA, Reis EM, Craig AW. CIP4 promotes metastasis in triplenegative breast cancer and is associated with poor patients prognosis. Oncotarget. 2015; 6: 9397-9408. doi: 10.18632/oncotarget.3351
73. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One. 2013; 8: e55910
74. Fulga V, Rudico L, Balica AR, Cimpean AM, Saptefrati L, Raica M. Invasive ductal carcinoma of no special type and its corresponding lymph node metastasis: do they have the same immunophenotypic profile? Pol J Pathol. 2015; 66: 30-37
75. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13: 674-690
76. Zhao YQ, Yin YQ, Liu J, Wang GH, Huang J, Zhu LJ, Wang JH. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer. Acta Pharmacol Sin. 2016; 37: 1237-1250
77. Shindikar A, Singh A, Nobre M, Kirolikar S. Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast Cancer. J Oncol. 2016; 2016: 9750785
78. Palumbo R, Sottotetti F, Bernardo A. Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients ? Ther Adv Med Oncol. 2016; 8: 209-229
79. Coyle KM, Murphy JP, Vidovic D, Vaghar-Kashani A, Dean CA, Sultan M, Clements D, Wallace M, Thomas ML, Hundert A, Giacomantonio CA, Helyer L, Gujar SA, et al. Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1. Oncotarget. 2016; 7: 44096-44112. doi: 10.18632/oncotarget.9858
80. Ali AM, Ansari JA, AbdelAziz NM, Aabozeed W, Warith A, Alsaleh K, Nabholtz JM. Triple Negative Breast Cancer: A Tale of Two Decades. Anticancer Agents Med Chem. 2016 Jul 25. [Epub ahead of print]
81. Zhang S, Chung WC, Miele L, Xu K. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer. Cancer Biol Ther. 2014; 15: 633-642
82. Anders CK, Abramson V, Tan T, Dent R. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Theraputics. Am Soc Clin Oncol Educ Book. 2016; 35: 34-42
83. Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, Lin SY. mTOR Inhibitors Supress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clin Cancer Res. 2016; 22: 1699-1712
84. Guo L, Li W, Zhu X, Ling Y, Qiu T, Dong L, Fang Y, Yang H, Ying J. PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. Springerplus. 2016; 5: 805
85. Li X, Wetherilt CS, Krishnamurti U, Yang J, Ma Y, Styblo TM, Meisel JL, Peng L, Siddiqui MT, Cohen C, Aneja R. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. Am J Clin Pathol. 2016; 146: 496-502
86. Stalker L, Pemberton J, Moorehead RA. Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors. Cancer Cell Int. 2014; 14: 89
87. Kulka J, Szekely B, Lukacs LV, Kiss O, Tokes AM, Vincze E, Turanyi E, Fillinger J, Hanzely Z, Arato G, Szendroi M, Gyorffy B, Szasz AM. Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Metastasis using Surgical Material: A Practice-Based Study. J Histochem Cytochem. 2016; 64: 256-267
88. Ito K, Park SH, Nayak A, Byerly JH, Irie HY. PTK6 Inhibition Suppresses Metastases of Triple-Negative Breast Cancer via SNAIL-Dependent E-Cadherin Regulation. Cancer Res. 2016; 76: 4406-4417
89. Gari HH, DeGala GD, Ray R, Lucia MS, Lambert JR. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion. Cancer Lett. 2016; 380: 505-512
90. Mathe A, Wong-Brown M, Morten B, Forbes JF, Braye SG, Avery-Kiejda KA, Scott RJ. Novel genes associated with lymph node metastasis in triple negative breast cancer. Sci Rep. 2015; 5: 15832